● The successful launch of the first nitric oxide therapeutic device in China has brought the most effective treatment for pulmonary hypertension in acute and critical illness.

● Novlead will lead the  development of supportive and interventional devices for the treatment of ARDS and heart failure associated with pulmonary hypertension.

● Two devices in Class III are expected to be launched next year.